This invention relates generally to an instrumentation and implant system for augmenting or supporting bones or other structures including, for example, a vertebral body or intervertebral disc space. More specifically, this invention relates to a porous or permeable containment device and associated methods and instrumentation for the treatment of compressed bone voids, more specifically, vertebral compression fractures and intervertebral disc space.
There are various pathologies which results in creation a bone the void including vertebral compression fractures, tumors in bony sections (e.g., vertebral bodies), and treatment of disc degeneration where the degenerated disc is removed and replaced with an implant. To fill the gap which is created during surgery/degeneration, insertion of a biomaterial is required for providing a bone growth environment (conductive/inductive) as well as for enhancing the mechanical stability of the bone.
Vertebral compression fractures (“VCF”) represent a common spinal injury and may result in prolonged disability. Generally speaking, VCF involves collapse of one or more vertebral bodies in the spine. VCF usually occurs in the lower vertebrae of the thoracic spine or the upper vertebrae of the lumbar spine and generally involves fracture of the anterior portion of the affected vertebral body. Such spinal compression fractures and related spinal deformities, if not successfully treated, can lead to deformation of the normal alignment or curvature, e.g., lordosis, of the affected area of the spine, as well as chronic complications and an overall adverse impact upon the quality of life for the patient. Until recently, doctors were limited to treating such compression fractures and related deformities with pain medications, bed rest, bracing or invasive spinal surgery.
More recently, minimally invasive surgical procedures for treating vertebral compression fractures, tumors in the bony sections (e.g., vertebral bodies), and disc degeneration have been developed. These procedures generally involve the insertion of a rigid cannula, needle or trocar into the interior of a collapsed or otherwise damaged vertebra. The cannula usually includes a lumen or central passage through which another tool, implant or filler material is passed in order to reposition and/or augment the vertebral body.
Delivering originally solid state biomaterial (e.g., autograft bone) through a minimally invasive access (cannula) to fill the created void has proven to be challenging procedure due to the geometrical constraints of the access cannula as well as friction between bone particles within the cannula during insertion. The most basic of these procedures is vertebroplasty. Vertebroplasty involves injecting a medical-grade bone cement (such as polymethylmethacrylate, a.k.a., PMMA) via a special bone needle into a fractured vertebra. The bone cement is injected with sufficient pressure to compress and displace cancellous bone tissue. However, the direction and containment of the injected cement can be difficult to control because the space the bone cement occupies is ill-defined, self-forming, and highly-dependent upon the internal composition of the cancellous bone. Additionally, vertebroplasty does not always reposition the fractured bone and therefore may not address the problem of spinal deformity due to fracture.
A number of more advanced treatments for vertebral compression fractures, tumors in the bony sections, and disc degeneration are known, and generally involve two phases: (1) reposition, or restoration of the original height/shape of the vertebral body/bone void (and consequent lordotic correction of the spinal curvature); and (2) augmentation, or addition of material to support or strengthen the fractured bone. Such procedures generally involve use of a cannula, catheter, needle, trocar or other introducer to provide access to the interior of the effected vertebral body.
Procedures, such as kyphoplasty, provide better bounding and control over injected bone cement, other procedures utilize devices for first forming cavities within the cancellous bone (and, accordingly, other interior body regions) prior to injecting bone cement into such a cavity. During balloon kyphoplasty (Kyphon, Inc.), an expandable body or balloon is deployed into the interior body region to form a cavity in, for example, cancellous bone tissue surrounded by fractured cortical bone. Kyphoplasty then achieves the reconstruction of the lordosis, or normal curvature, by inflating the balloon, which expands within the vertebral body restoring it to its original height. These expandable body devices effectively compress and displace the cancellous bone to form an interior cavity that then receives a filling material intended to provide renewed interior structural support for cortical bone.
A common drawback of most systems for repositioning and augmenting damaged vertebrae/bone voids is that they involve the use of multiple complex instruments introduced through rigid introducers. These introducers limit the surgeon's ability to access portions of the patient's spine. Similarly, these systems do not allow the surgeon to control the location and composition of the bone cerement provided to the bone cavity. Furthermore, delivering bone graft and solid state material into the intervertebral disc space through a minimally invasive access is challenging as the solid state material tends to jam on the way to the intended point. Accordingly, there remains a need in the art to provide a safe and effective apparatus and methods for minimally invasive repositioning of and osteopathic augmentation of vertebral bodies to restore lordosis of the spine.
Presented are systems and methods for minimally invasive vertebral augmentation and restoration of spinal lordosis. An aspect of the present invention is directed to an apparatus including a porous or permeable membrane is provided into an interior volume/void in a targeted vertebral body. The membrane configured to receive bone filler material thereby restoring the anatomy of the targeted vertebral body. The apparatus including an expandable membrane sized and configured to be located within the cavity in the patient's bone, the expandable membrane having an interior cavity for receiving the bone filler material. The device further includes a delivery cannula in fluid communication with the membrane for providing bone filler material to the expandable membrane. The device also includes an evacuation cannula in fluid communication with the membrane for receiving a portion of the provided bone filler material from the membrane.
Another aspect of the present disclosure is directed to a method of augmenting void in a patient's bone, e.g., a void in a vertebral body. The method may include placing an expandable membrane into an interior void in a vertebral body and providing bone filler material to through a delivery cannula to the membrane. The membrane may be expanded by injection of an amount of bone filler material and a portion of the bone filler material may be removed from the membrane via an evacuation cannula.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
The device is explained in even greater detail in the following drawings. The drawings are merely examples to illustrate the structure of preferred devices and certain features that may be used singularly or in combination with other features. The invention should not be limited to the examples shown.
Like reference symbols in the various drawings indicate like elements.
Certain terminology is used in the following description for convenience only and is not limiting. The words “right”, “left”, “lower”, and “upper” designate direction in the drawings to which reference is made. The words “inner”, “outer” refer to directions toward and away from, respectively, the geometric center of the described feature or device. The words “distal” and “proximal” refer to directions taken in context of the item described and, with regard to the instruments herein described, are typically based on the perspective of the surgeon using such instruments. The terminology includes the above-listed words, derivatives thereof, and words of similar import.
In addition, various components may be described herein as extending horizontally along a longitudinal direction “L” and lateral direction “A”, and vertically along a transverse direction “T”. Unless otherwise specified herein, the terms “lateral”, “longitudinal”, and “transverse” are used to describe the orthogonal directional components of various items. It should be appreciated that while the longitudinal and lateral directions are illustrated as extending along a horizontal plane, and that the transverse direction is illustrated as extending along a vertical plane, the planes that encompass the various directions may differ during use. Accordingly, the directional terms “vertical” and “horizontal” are used to describe the components merely for the purposes of clarity and illustration and are not meant to be limiting.
Certain examples of the invention will now be described with reference to the drawings. In general, such embodiments relate to a porous or permeable membrane inserted into an interior volume/void in a targeted vertebral body and providing bone filler material to the device to restore the anatomy of the targeted vertebral body.
Filling of the cavity formed in the vertebral body V (or intervertebral disc space V) and the stabilization of the targeted vertebral body V is accomplished by the injection of the bone filler material 140, the expansion of the membrane 110, and removal of all or a portion of the carrier fluid 144 such that the solid material 142 accumulates in the membrane 110, as will be described in greater detail below. The membrane 110 can remain in the void or can be removed to leave only the bone filler material 140. It is also contemplated that the expansion of the membrane 110 will include the controlled secretion of the bone filler material 140 out of or through the pores provided in the membrane 110.
The membrane 110 can be composed of a flexible material such that the membrane 110 expands when filled with the bone filler material 140. For example, the membrane 110 can be expanded from a first, non-expanded, configuration to a second, expanded, configuration via injection of the bone filler material 140 into the membrane 110. In the first, non-expanded, configuration, the membrane 110 can be sized and configured for insertion into interior cavity through a minimally invasive apparatus, e.g., a cannula. The membrane 110 can be flexible such that the shape of the second, expanded, configuration of the membrane 110 can be defined by the shape/volume of the bone cavity. In another example, the membrane 110 can be semi-constrained or selectively reinforced such that the second, expanded, configuration of the membrane 110 can be predefined. For example, the expanded configuration of the membrane 110 can define a sphere, a cylinder, a cone, a square, a rectangle, a torus, a dog bone, a regular shape, an irregular shape, or any other desired shape. In a further example, the expanded configuration of the membrane 110 can include a partially defined shape. That is, the expanded membrane 110 can define a predetermined shape and also be flexible and/or deformable based on the shape/volume defined by the bone cavity. In another example, the membrane 110 can be constructed from a shape memory material such that the membrane 110 has a first, flexible, configuration prior to insertion and a second, previously defined, shape after insertion.
As illustrated in
The delivery cannula 120 is in communication with the membrane 110 and is sized and configured to provide bone filler material 140 (carrier fluid 144 and/or solid material 142) to the expandable membrane 110. The delivery cannula 120 can be sized to deliver both the solid material 142 and the carrier fluid 144 of the bone filler material 140 to the membrane 110. The evacuation cannula 130 is also in fluid communication with the membrane 110 and is sized and configured to receive a portion of the bone filler material 140 provided to the membrane 110 by the delivery cannula 120. The evacuation cannula 130 can be sized to receive the carrier fluid 144 and/or solid material 142 particles of a predetermined size. The evacuation cannula 130 can be used to remove bone filler material 140 (carrier fluid 144 and/or solid material 142) from the membrane 110 during and/or after expansion of the membrane 110 within the bone cavity. For example, bone filler material 140 may be removed during expansion in an effort to maintain a desired pressure and/or desired expansion of the membrane 110. Bone filler material 140 may also be removed from the membrane 110 after expansion. For example, all or a portion of the carrier fluid 144 may be removed from the membrane 110 such that the solid material 142 of the bone filler material 140 accumulates in the membrane 110. In an other example, carrier fluid 144 along with solid material 142 of a particular size may be removed via the evacuation cannula 130 such that solid material 142 of an other size remains in the membrane 110.
It is contemplated that the delivery cannula 120 and the evacuation cannula 130 are releasably coupled to the membrane 110 such that once the desired amount of bone filler material 140 has been delivered to the membrane 110 and the expanded membrane 110 is at its desired configuration, the delivery cannula 120 and the evacuation cannula 130 can be removed/released from the membrane 110 and the membrane 110 can remain as an implant in the cavity.
To facilitate delivery bone filler material 140 to the membrane 110, the apparatus 100 can include an input member 150. As illustrated in
To facilitate removal of bone filler material 140 from the membrane 110, the apparatus 100 can include an output member 160. As illustrated in
As illustrated in the example apparatus 100 of
In another example apparatus 100 illustrated in
In a further example, the membrane 110 can be constructed from a flexible material and include a withdraw element 170 capable of withdrawing the flexible membrane 110 off the filler material 140.
In another example (now shown), the withdraw element 170 is coupled to the membrane 110 such that as the withdraw element 170 is moved is a direction towards the proximal end 118, the membrane 100 is removed from the filler material 140 without folding back onto itself. For example, the withdraw element 170 can be coupled to the proximal end 118 of the membrane 110 and/or along the length of the membrane 110. Movement of the withdraw element 170 causes the membrane 110 to release from the delivery cannula 120 and move over the filler material 140 and the delivery cannula 120 in a direction towards the proximal end 118 of the apparatus 100.
In operation, the bone filler material 140 can be provided to the membrane 110 via the delivery cannula 120. The carrier fluid 144 (and possibly some solid material 142 depending in contact area defined by the evacuation cannula 130) is removed from the membrane 110. Once the filler material 140 is sufficiently set/formed within the bone cavity, the withdraw element 170 can be used to drawn the flexible material of the membrane 110 off the set filler material leaving only the filler material within bone cavity.
In operation, bone filler material 140 is provided to the membrane 110 via the delivery cannula 120 in the direction of arrow A. Solid material 142 will collect within the interior volume defined by the inner layer 110b. The carrier fluid 144 (and possibly some solid material 142 depending on the area defined by the openings in the inner and/or outer layers 110b, 110a and/or the opening in the ring 154) is removed from the membrane 110. For example, where the inner layer 110b and/or outer layer 110a are permeable, the carrier fluid 144 and/or solid material 142 (of a particular size) can pass from the inner volume of the membrane 110 to the evacuation cannula 130, in the direction of arrows B. It is also contemplated that carrier fluid 144 and/or solid material 142 (of a particular size) can pass through the opening in the ring 154 and into the void in the direction of arrow C. Where the outer layer 110a is permeable, carrier fluid 144 and/or solid material 142 that has passed through the opening in the ring 154 can also pass into the evacuation cannula 130 via the openings 114 in the outer layer 110a. The carrier fluid 144 and/or solid material 142 is then drawn through the evacuation cannula 130 in the direction of arrows D. Once the filler material 140 is sufficiently set/formed within the inner volume of the membrane 110, the membrane 110 can be removed from the set filler material, leaving the filler material 140 within the cavity. The evacuation cannula 130/outer cannula of the apparatus 100 can facilitate removal of the membrane 110 from the filler material. For example, as evacuation cannula 130/outer cannula of the apparatus 100 can be moved with respect to the delivery cannula 120/inner cannula of the apparatus 110, the outer layer 110a is moved with respect to the inner layer 110b. In an example apparatus 100, as the evacuation cannula 130 is moved in the direction of arrows E, away from the membrane 100, the outer layer 110a (and membrane 110) is removed from the filler material 140. The ring 154 can be made of a fragile material that such that it will fracture when sufficient force is applied from the outer layer 110a/evacuation cannula 130. Once the ring 154 is fractured, the membrane 100 (inner layer 110b and outer layer 110a) can be withdrawn off of the filler material. Once removed from the filler material 140, the inner layer 110a can separate from the delivery cannula 120 and the entirety of the membrane 110 removed from the filler material 140, leaving only the filler material 140 within the cavity. In another example, the ring 154 can be constructed from a flexible material such that the ring 154 stretches/flexes as the membrane 110 is removed from the filler material 140.
In use, the membrane 110, in its first, non-expanded, configuration is inserted preferably via a minimally invasively apparatus (e.g., cannula) into a targeted zone.
A portion of the bone filler material 140 (e.g., the carrier fluid 144 and/or solid material 142 of a particular size) may be removed from the membrane 110 through the evacuation cannula 130 (direction of arrow B in
The outer surface of the membrane 110 can be porous such that an amount of bone filler material 140 is secreted out of or through the membrane 110. In another example, the pores/openings 114 can be located on the body portion 112 of the membrane 110 such that the bone filler material 140 is directionally secreted from the membrane 110. In an example apparatus, a relatively small amount of bone filler material 140 may be secreted out of or through the membrane 110 via one or more pores/openings 114 formed in the membrane 110. Once secreted, the bone filler material 140 can cure to form a cement layer around the membrane 110 that integrates with the surrounding bone tissue.
As outlined above, the bone filler material 140 can include a radiolucent material to enhance visibility of the membrane 110 during radiographic imaging. Accordingly, radiographic (x-ray) imaging may be used during expansion of the membrane 110 to determine the desired distribution of filler material 140. Likewise, radiographic (x-ray) imaging may be used during injection of filler material 140 to determine the desired repositioning of the intervertebral disc space V and expansion of the membrane 110.
Once the bone filler material 140 is inserted into the membrane 110 (and the desired portion of carrying fluid 144 and/or solid material 142 has been removed), the bone filler material 140 begins to cure within the bone cavity. In an example apparatus, the membrane 110, enclosing the cured bone filler material 140, remains within the bone cavity of the targeted vertebral body V/intervertebral disc space V and is considered part of the implanted material. This implant-type membrane 110 can assist in load bearing and structural support of the vertebral body V/intervertebral disc space V as the bone filler material 140 cures. In another example, the implant-type membrane 110 is constructed from a bioresorbable material that is absorbed, over time, into the body. In a further example, the membrane 110 is constructed from a flexible material such that, as the bone filler material 140 cures within the cavity, the flexible material of the membrane 110 is removed from the cured (and/or partially cured) bone filler material 140, leaving the bone filler material 140 within the cavity. In such an example, the membrane 100 can be considered part of the apparatus 100 for facilitating delivery and placement of the bone filler material to the void.
As outlined above, the membrane 110, delivery cannula 120, and evacuation cannula 130 may be composed of a biocompatible material known including, for example, metals such as titanium, titanium alloys, stainless steel and cobalt chromium, cobalt chromium molybdenum (CoCrMo), or other metals. Other materials include, for example, composites, polymers, or ceramics. In one example, one or more components of the apparatus 100 can be constructed from a radiopaque material including, for example, stainless steel such as 17-4PH stainless steel. Likewise, one or more components described herein can be constructed from a radiolucent material to enhance visibility of the assembly during radiographic imaging. Example radiolucent materials can include “life science” grade PEEK (Ketron 450G PEEK). Life science grade PEEK can improve wear and abrasion characteristics as well as provide high yield strength. A coating may be added or applied to the various components described herein to improve physical or chemical properties, such as a plasma-sprayed titanium coating or Hydroxypatite. Moreover, skilled artisans will also appreciate that the various components herein described can be constructed with any dimensions desirable for implantation and cavity creation.
While the foregoing description and drawings represent the preferred embodiment of the present invention, it will be understood that various additions, modifications, combinations and/or substitutions may be made therein without departing from the spirit and scope of the present invention as defined in the accompanying claims. In particular, it will be clear to those skilled in the art that the present invention may be embodied in other specific forms, structures, arrangements, proportions, and with other elements, materials, and components, without departing from the spirit or essential characteristics thereof. One skilled in the art will appreciate that the invention may be used with many modifications of structure, arrangement, proportions, materials, and components and otherwise, used in the practice of the invention, which are particularly adapted to specific environments and operative requirements without departing from the principles of the present invention. In addition, features described herein may be used singularly or in combination with other features. The presently disclosed embodiments are, therefore, to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims and not limited to the foregoing description.
It will be appreciated by those skilled in the art that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications within the spirit and scope of the present invention, as defined by the following claims.
This application is a continuation of U.S. application Ser. No. 14/025,448 (issued as U.S. Pat. No. 9,539,041), filed Sep. 12, 2013, entitled “Minimally Invasive Biomaterial Injection System,” the disclosure of which is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
2381050 | Hardinge | Dec 1943 | A |
3701703 | Zimmer et al. | Oct 1972 | A |
3867728 | Stubstad et al. | Feb 1975 | A |
4055029 | Kalbow et al. | Oct 1977 | A |
4311146 | Wonder | Jan 1982 | A |
4364392 | Strother et al. | Dec 1982 | A |
4735625 | Davidson | Apr 1988 | A |
4755184 | Silverberg | Jul 1988 | A |
4819637 | Dormandy, Jr. et al. | Apr 1989 | A |
4820349 | Saab | Apr 1989 | A |
4969888 | Scholten et al. | Nov 1990 | A |
5041114 | Chapman et al. | Aug 1991 | A |
5049132 | Shaffer et al. | Sep 1991 | A |
5059193 | Kuslich | Oct 1991 | A |
5098381 | Schneider | Mar 1992 | A |
5108404 | Scholten et al. | Apr 1992 | A |
5176692 | Wilk et al. | Jan 1993 | A |
5192326 | Bao et al. | Mar 1993 | A |
5390683 | Pisharodi | Feb 1995 | A |
5411475 | Atala et al. | May 1995 | A |
5443496 | Schwartz et al. | Aug 1995 | A |
5514092 | Forman et al. | May 1996 | A |
5549679 | Kuslich | Aug 1996 | A |
5571189 | Kuslich | Nov 1996 | A |
5599301 | Jacobs et al. | Feb 1997 | A |
5601593 | Freitag | Feb 1997 | A |
5674295 | Ray et al. | Oct 1997 | A |
5693100 | Pisharodi | Dec 1997 | A |
5707390 | Bonutti | Jan 1998 | A |
5759191 | Barbere | Jun 1998 | A |
5800392 | Racchini | Sep 1998 | A |
5827289 | Reiley et al. | Oct 1998 | A |
5830228 | Knapp et al. | Nov 1998 | A |
5893850 | Cachia | Apr 1999 | A |
5972015 | Scribner et al. | Oct 1999 | A |
5993484 | Shmulewitz | Nov 1999 | A |
6096038 | Michelson | Aug 2000 | A |
6127597 | Beyar et al. | Oct 2000 | A |
6179856 | Barbere | Jan 2001 | B1 |
6235043 | Reiley et al. | May 2001 | B1 |
6241734 | Scribner et al. | Jun 2001 | B1 |
6248110 | Reiley et al. | Jun 2001 | B1 |
6293960 | Ken | Sep 2001 | B1 |
6306177 | Felt et al. | Oct 2001 | B1 |
6395032 | Gauchet | May 2002 | B1 |
6402784 | Wardlaw | Jun 2002 | B1 |
6440138 | Reiley et al. | Aug 2002 | B1 |
6478800 | Fraser et al. | Nov 2002 | B1 |
6547804 | Porter et al. | Apr 2003 | B2 |
6558390 | Cragg | May 2003 | B2 |
6565606 | Bruce et al. | May 2003 | B1 |
6613054 | Scribner et al. | Sep 2003 | B2 |
6620162 | Kuslich et al. | Sep 2003 | B2 |
6632235 | Weikel et al. | Oct 2003 | B2 |
6638246 | Naimark et al. | Oct 2003 | B1 |
6663647 | Reiley et al. | Dec 2003 | B2 |
6679886 | Weikel et al. | Jan 2004 | B2 |
6706069 | Berger | Mar 2004 | B2 |
6716216 | Boucher et al. | Apr 2004 | B1 |
6719761 | Reiley et al. | Apr 2004 | B1 |
6726691 | Osorio et al. | Apr 2004 | B2 |
6733532 | Gauchet et al. | May 2004 | B1 |
6736793 | Meyer et al. | May 2004 | B2 |
6740093 | Hochschuler et al. | May 2004 | B2 |
6852095 | Ray | Feb 2005 | B1 |
6855153 | Saadat | Feb 2005 | B2 |
6863672 | Reiley et al. | Mar 2005 | B2 |
6899719 | Reiley et al. | May 2005 | B2 |
6969404 | Ferree | Nov 2005 | B2 |
6981981 | Reiley et al. | Jan 2006 | B2 |
7001431 | Bao et al. | Feb 2006 | B2 |
7011684 | Eckman | Mar 2006 | B2 |
7025771 | Kuslich et al. | Apr 2006 | B2 |
7044954 | Reiley et al. | May 2006 | B2 |
7097648 | Globerman et al. | Aug 2006 | B1 |
7153307 | Scribner et al. | Dec 2006 | B2 |
7166121 | Reiley et al. | Jan 2007 | B2 |
7175627 | Lin et al. | Feb 2007 | B2 |
7175628 | Lin et al. | Feb 2007 | B2 |
7175629 | Lin et al. | Feb 2007 | B2 |
7226481 | Kuslich | Jun 2007 | B2 |
7226648 | Al Ghatta et al. | Jun 2007 | B2 |
7241303 | Reiss et al. | Jul 2007 | B2 |
7261720 | Stevens et al. | Aug 2007 | B2 |
7655010 | Serhan et al. | Feb 2010 | B2 |
7699894 | O'Neil | Apr 2010 | B2 |
8043381 | Hestad et al. | Oct 2011 | B2 |
8057528 | Parker | Nov 2011 | B2 |
8147517 | Trieu et al. | Apr 2012 | B2 |
8167944 | Kim | May 2012 | B2 |
8357384 | Behnam et al. | Jan 2013 | B2 |
8403937 | Schwardt | Mar 2013 | B2 |
8518115 | Chavatte et al. | Aug 2013 | B2 |
9539042 | Paris | Jan 2017 | B2 |
20020058947 | Hochschuler et al. | May 2002 | A1 |
20020068974 | Kuslich et al. | Jun 2002 | A1 |
20030187473 | Berenstein et al. | Oct 2003 | A1 |
20030220649 | Bao et al. | Nov 2003 | A1 |
20030220666 | Mirigian et al. | Nov 2003 | A1 |
20040054414 | Trieu et al. | Mar 2004 | A1 |
20040073308 | Kuslich et al. | Apr 2004 | A1 |
20040097930 | Justis et al. | May 2004 | A1 |
20040098017 | Saab et al. | May 2004 | A1 |
20040102774 | Trieu | May 2004 | A1 |
20040143288 | Searle | Jul 2004 | A1 |
20040167561 | Boucher et al. | Aug 2004 | A1 |
20040167625 | Beyar et al. | Aug 2004 | A1 |
20040210297 | Lin et al. | Oct 2004 | A1 |
20040215343 | Hochschuler et al. | Oct 2004 | A1 |
20040215344 | Hochschuler et al. | Oct 2004 | A1 |
20040220615 | Lin et al. | Nov 2004 | A1 |
20050010297 | Watson et al. | Jan 2005 | A1 |
20050070911 | Carrison et al. | Mar 2005 | A1 |
20050143827 | Globerman et al. | Jun 2005 | A1 |
20050209595 | Karmon | Sep 2005 | A1 |
20050209629 | Kerr et al. | Sep 2005 | A1 |
20050234498 | Gronemeyer et al. | Oct 2005 | A1 |
20050273049 | Krulevitch et al. | Dec 2005 | A1 |
20060009844 | Bloemer et al. | Jan 2006 | A1 |
20060079905 | Beyar et al. | Apr 2006 | A1 |
20060100706 | Shadduck | May 2006 | A1 |
20060106459 | Truckai et al. | May 2006 | A1 |
20060149379 | Kuslich et al. | Jul 2006 | A1 |
20060155296 | Richter | Jul 2006 | A1 |
20060173464 | Ellman et al. | Aug 2006 | A1 |
20060182780 | Riley et al. | Aug 2006 | A1 |
20060190083 | Arnin et al. | Aug 2006 | A1 |
20060217736 | Kaneko et al. | Sep 2006 | A1 |
20060229625 | Truckai et al. | Oct 2006 | A1 |
20060235425 | Lin et al. | Oct 2006 | A1 |
20060271061 | Beyar et al. | Nov 2006 | A1 |
20060293750 | Sherman et al. | Dec 2006 | A1 |
20070055266 | Osorio et al. | Mar 2007 | A1 |
20070055267 | Osorio et al. | Mar 2007 | A1 |
20070055280 | Osorio et al. | Mar 2007 | A1 |
20070055284 | Osorio et al. | Mar 2007 | A1 |
20070055285 | Osorio et al. | Mar 2007 | A1 |
20070093899 | Dutoit et al. | Apr 2007 | A1 |
20070156251 | Karmon | Jul 2007 | A1 |
20070168031 | Hudgins et al. | Jul 2007 | A1 |
20070213760 | Hayes et al. | Sep 2007 | A1 |
20070219490 | Pepper et al. | Sep 2007 | A1 |
20070233258 | Hestad et al. | Oct 2007 | A1 |
20070282443 | Globerman et al. | Dec 2007 | A1 |
20080027546 | Semler et al. | Jan 2008 | A1 |
20080086133 | Kuslich et al. | Apr 2008 | A1 |
20080108860 | Bell et al. | May 2008 | A1 |
20080154273 | Shadduck et al. | Jun 2008 | A1 |
20080249604 | Donovan et al. | Oct 2008 | A1 |
20090069850 | Fuerderer | Mar 2009 | A1 |
20100262240 | Chavatte et al. | Oct 2010 | A1 |
20100274255 | Donovan et al. | Oct 2010 | A1 |
20110218544 | Mirza | Sep 2011 | A1 |
20130230454 | Gardner | Sep 2013 | A1 |
Number | Date | Country |
---|---|---|
0493789 | Jul 1992 | EP |
0872257 | Oct 1998 | EP |
1995005209 | Feb 1995 | WO |
1998056301 | Dec 1998 | WO |
2001076514 | Oct 2001 | WO |
2002043628 | Jun 2002 | WO |
2003007853 | Jan 2003 | WO |
2005048856 | Jun 2005 | WO |
2006034396 | Mar 2006 | WO |
2009084109 | Jul 2009 | WO |
Entry |
---|
Cotten, M.D., Anne, et al., “Percutaneous Vertebroplasty for Osteolytic Metastases and Myeloma: Effects of the Percentage of Lesion Filling and the Leakage of Methyl Methacrylate at Clinical Follow-up,” Radiology, vol. 200, 1996, pp. 525-530. |
Cotten, M.D., Anne, et al., “Preoperative Percutaneous Injection of Methyl Methacrylate and N-Butyl Cyanoacrylate in Vertebral Hemangiomas,” AJNR, vol. 17, 1996, pp. 137-142. |
Gangi, Afshin, et al., “Percutaneous Vertebroplasty Guided by a Combination of CT and Fluoroscopy,” AJNR, vol. 15, Jan. 1994, pp. 83-86. |
Maciunas, M.D., R.J., “Endovascular Neurological Intervention,” American Association of Neurological Surgeons, 1995, pp. 153-158. |
Jensen, Mary E., et al., “Percutaneous Polymethylmethacrylate Vertebroplasty in the Treatment of Osteoporotic Vertebral Body Compression Fractures: Technical Aspects,” AJNR, vol. 18, No. 10, Nov.-Dec. 1997, pp. 1897-1904. |
Saab, Mark A., “Applications of High-Pressure Balloons in the Medical Device Industry,” 1999, 19 pages. |
International Search Report, dated Nov. 28, 2014, received in connection with International Patent Application No. PCT/US2014/053691. |
International Search Report, dated Jun. 15, 2009, received in connection with International Patent Application No. PCT/US2008/083350. |
International Preliminary Report on Patentability and Written Opinion, dated May 18, 2010, in International Application No. PCT/US2008/083350. |
Number | Date | Country | |
---|---|---|---|
20170112629 A1 | Apr 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14025448 | Sep 2013 | US |
Child | 15401229 | US |